MediciNova gets bounce after revealing clinical plan for MS therapy

With new clarity on a clinical plan for a single Phase III study, investors appeared satisfied with MediciNova's intention to develop multiple sclerosis therapy ibudilast for a

Read the full 278 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE